Chemistry:Milvexian
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | BMS-986177, JNJ-70033093 |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 11.4–18.1 h[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C28H23Cl2F2N9O2 |
| Molar mass | 626.45 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Milvexian is a factor XIa inhibitor which acts as an anticoagulant. It is taken by mouth. As of late 2021, it was under study for the prevention of blood clots in patients undergoing surgery.[2] In 2018–2023, Bristol-Myers Squibb studied milvexian for the prevention of stroke.[3]
References
- ↑ "First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor". Clinical and Translational Science 15 (2): 330–342. September 2021. doi:10.1111/cts.13148. PMID 34558200.
- ↑ "Milvexian for the Prevention of Venous Thromboembolism". The New England Journal of Medicine 385 (23): 2161–2172. November 2021. doi:10.1056/NEJMoa2113194. PMID 34780683.
- ↑ "A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (AXIOMATIC-SSP)". U.S. National Library of Medicine. https://classic.clinicaltrials.gov/ct2/show/results/NCT03766581.
 |  |
